Evidence map›Paper›PMID 34462158›Full record

ArticleHuman immunology2022

HLA repertoire of 115 UAE nationals infected with SARS-CoV-2.

Halima Alnaqbi, Guan K Tay, Herbert F Jelinek, Amirtharaj Francis, Eman Alefishat, Sarah El Haj Chehadeh, Amna Tahir Saeed, Mawada Hussein, Laila Salameh, Bassam H Mahboub and 4 more

Abstract readComparative Study
In one paragraph

Article in Human immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. HLA Genotypes in Patients with Infection Caused by Different Strains of SARS-CoV-2.International journal of environmental research and public health · 2022
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Halima AlnaqbiCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Guan K TayCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Division of Psychiatry, Faculty of Health and Medical Sciences, the University of Western Australia, Crawley, Western Australia, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Herbert F JelinekCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Heath Engineering Innovation Center, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Amirtharaj FrancisClinical Services, Medical Affairs, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Eman AlefishatCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biopharmaceutics & Clinical Pharmacy, University of Jordan, Amman, Jordan.
Sarah El Haj ChehadehCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Amna Tahir SaeedDubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates.
Mawada HusseinDubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates.
Laila SalamehDubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates.
Bassam H MahboubDubai Health Authority, Rashid Hospital, Dubai, United Arab Emirates.
Maimunah UddinDepartment of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Nawal AlkaabiDepartment of Pediatric Infectious Disease, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Habiba S AlsafarCenter for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering, College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Department of Genetics and Molecular Biology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates. Electronic address: habiba.alsafar@ku.ac.ae.
UAE COVID-19 Collaborative Partnership

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The class I and class II Human Leucocyte Antigens (HLA) are an integral part of the host adaptive immune system against viral infections. The characterization of HLA allele frequency in the population can play an important role in determining whether HLA antigens contribute to viral susceptibility. In this regard, global efforts are currently underway to study possible correlations between HLA alleles with the occurrence and severity of SARS-CoV-2 infection. Specifically, this study examined the possible association between specific HLA alleles and susceptibility to SARS-CoV-2 in a population from the United Arab Emirates (UAE). The frequencies of HLA class I (HLA-A, -B, and -C) and HLA class II alleles (HLA-DRB1 and -DQB1); defined using Next Generation Sequencing (NGS); from 115 UAE nationals with mild, moderate, and severe SARS-CoV-2 infection are presented here. HLA alleles and supertypes were compared between hospitalized and non-hospitalized subjects. Statistical significance was observed between certain HLA alleles and supertypes and the severity of the infection. Specifically, alleles HLA-B*51:01 and HLA-A*26:01 showed a negative association (suggestive of protection), whilst genotypes HLA-A*03:01, HLA-DRB1*15:01, and supertype B44 showed a positive association (suggestive of predisposition) to COVID-19 severity. The results support the potential use of HLA testing to differentiate between patients who require specific clinical management strategies.

Indexed as

AdolescentAdultAgedAged, 80 and overCOVID-19FemaleGene FrequencyGenetic Predisposition to DiseaseHaplotypesHLA AntigensHost-Pathogen InteractionsHumansMaleMiddle AgedProtective FactorsRisk AssessmentHLA AntigensCOVID-19Human Leucocyte AntigenMajor histocompatibility complexSARS-CoV-2United Arab Emirates

Identifiers

PMID34462158
PMCPMC8391094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.